- Wednesday, October 16, 2024
Kintara Therapeutics, a San Diego-based biopharmaceutical company specializing in oncology drugs, recently announced the suspension of its brain-cancer treatment candidate, VAL-083, after the drug failed to outperform current standards of care in glioblastoma. As a result, the company will now concentrate its resources on its promising breast-cancer treatment candidate, REM-001.
The decision to suspend the development of VAL-083 was made based on preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment study. Kintara aims to optimize shareholder value by exploring strategic options while evaluating the full results of the glioblastoma study, which are expected by the end of the first quarter or early second quarter of 2024.
Meanwhile, Kintara is preparing to enroll the first patient in a 15-patient study for REM-001, focusing on the treatment of cutaneous metastatic breast cancer. The company's commitment to this program is evident through its recent receipt of a $2 million grant from the National Institute of Health's Small Business Innovation Research program specifically for the clinical development of REM-001 as a photodynamic therapy photosensitizer agent.
More Posts
All Rights Reserved © 2024
Post a comment